CSE:AGN - Post Discussion
Post by
StockHawk1 on Jan 18, 2023 3:44pm
AGN doses first DMT participant (video)
Algernon Pharmaceuticals (AGN.c AGNPF) has started the first phase of its clinical study on DMT for the treatment of stroke.
Currently, healthy patients are being given DMT to identify a safe and tolerable non-psychedelic dose.
In the next phase of the study, AGN will give stroke survivors these safe DMT doses.
Be the first to comment on this post